Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)
China · Delayed Price · Currency is CNY 4.580
+0.040 (0.88%)
Jul 29, 2026, 3:04 PM CST
SHE:002424 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 2,932 | 3,049 | 3,825 | 4,263 | 3,540 | 3,111 |
Revenue Growth | -9.87% | -20.30% | -10.27% | 20.42% | 13.79% | 0.75% |
Gross Profit Gross Profit Growth | 1,298 | 1,391 | 2,166 | 2,310 | 2,103 | 1,840 |
Operating Income Operating Income Growth | 106.6 | 108 | 19.62 | -402.34 | 223.43 | 222.85 |
Net Income Net Income Growth | -100.35 | -104.37 | 33.62 | -414.51 | 138.47 | 118.48 |
Earnings Per Share EPS Growth | -0.07 | -0.08 | 0.02 | -0.30 | 0.10 | 0.08 |
EPS Growth | - | - | - | - | 25.00% | -27.27% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Intersegment Elimination Intersegment Elimination Growth | -658.25 | - | - | - | - |
Industrial Industrial Growth | 2,487 | 2,274 | 2,465 | 2,291 | 2,863 |
Others Others Growth | 22.8 | 36.31 | 45.43 | 32.37 | 28.4 |
Medical Institutions Medical Institutions Growth | 67.86 | 64.22 | 60.08 | 51.78 | 57.39 |
Commercial Business Commercial Business Growth | 1,129 | 1,451 | 1,693 | 1,165 | 162.38 |
Total Total Growth | 3,049 | 3,825 | 4,263 | 3,540 | 3,111 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 180.67 | 354.8 | 395.63 | 417.94 | 605.02 | 465.63 |
Total Debt Total Debt Growth | 1,132 | 1,229 | 1,796 | 1,686 | 1,567 | 1,715 |
Net Cash (Debt) Net Cash Growth | -950.98 | -874.66 | -1,400 | -1,268 | -962.25 | -1,249 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.70 | -0.67 | -0.83 | -0.92 | -0.69 | -0.84 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 595.95 | 748.72 | 9.02 | 125.77 | 502.15 | 324.92 |
Capital Expenditures CapEx Growth | -126.22 | -125.24 | -42.02 | -104.12 | -68.45 | -425.73 |
Free Cash Flow Free Cash Flow Growth | 469.73 | 623.47 | -33 | 21.65 | 433.7 | -100.81 |
Free Cash Flow Growth | 43.43% | - | - | -95.01% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 44.28% | 45.63% | 56.61% | 54.19% | 59.39% | 59.13% |
Operating Margin | 3.64% | 3.54% | 0.51% | -9.44% | 6.31% | 7.16% |
Pretax Margin | 1.37% | 1.33% | 1.75% | -11.57% | 4.49% | 4.55% |
Profit Margin | -3.42% | -3.42% | 0.88% | -9.72% | 3.91% | 3.81% |
FCF Margin | 16.02% | 20.45% | -0.86% | 0.51% | 12.25% | -3.24% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | 156.31 | - | 82.36 | 89.65 |
Forward PE | - | 11.00 | 11.00 | 29.49 | 17.71 | 17.71 |
P/FCF Ratio | 13.31 | 9.52 | - | 519.03 | 26.30 | - |
PS Ratio | 2.13 | 1.95 | 1.37 | 2.64 | 3.22 | 3.41 |